New paradigms in adjuvant systemic therapy of breast cancer

Endocrine-Related Cancer

Volumn 10, Issue 1, 2003, Pages 75-89

  Thomas, E ^a   Hortobagyi, G N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; LETROZOLE; MELPHALAN; METHOTREXATE; PACLITAXEL; PREDNISONE; TAMOXIFEN; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CATHETER ABLATION; CLINICAL TRIAL; DOSE RESPONSE; ENDOMETRIUM CARCINOMA; HEART DISEASE; HOT FLUSH; HUMAN; LEUKEMIA; LONG TERM CARE; LYMPH NODE METASTASIS; META ANALYSIS; REVIEW; SEPSIS; STEM CELL TRANSPLANTATION; THROMBOEMBOLISM; VAGINA BLEEDING;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ENZYME INHIBITORS; FEMALE; HUMANS;

EID: 0037365681     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0100075     Document Type: Review

References (97)

1. A'Hern R, Smith I & Ebbs S 1993 Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. British Journal of Cancer 67 801-805.
2. Albain K, Green S, Ravdin P, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, Abeloff M, Norton L, Henderson I, Lew D, Livingston R, Martino S & Osborne C 2002 Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG 8814). Proceedings of the American Society of Clinical Oncology Abstract 143.
3. ATAC (Arimidex, Tamoxifen, or in Combination) Trialists' Group 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 2131-2139.
4. Bezwoda W 1999 Randomized controlled trial of high-dose chemotherapy (HD-CNVp) versus standard dose CAF chemotherapy for high-risk, surgically treated, primary breast cancer. Proceedings of the American Society of Clinical Oncology plenary session.
5. Boccardo F, Rubagotti A, Amoroso D, Sismondi P, Genta F, Nenci I, Piffanelli A, Farris A, Castagnetta L & Traina A 1992 Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA trial. European Journal of Cancer 28 673-680.
6. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P, Giai M, Genta F, Pacini P, Distante V, Bolognesi A, Aldrighetti D & Farris A 2000 Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. Journal of Clinical Oncology 18 2718-2727.
7. Bonadonna G & Valagussa P 1981 Dose-response effect of adjuvant chemotherapy in breast cancer. New England Journal of Medicine 304 10-15.
8. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R & Veronesi U 1976 Combination chemotherapy as an adjuvant treatment in operable breast cancer. New England Journal of Medicine 294 405-410.
9. Bonadonna G, Valagussa P, Moliterni A, Zambetti M & Brambilla C 1995 Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. New England Journal of Medicine 332 901-906.
10. Bryant J, Fisher B & Dignam J 2001 Duration of adjuvant tamoxifen therapy. Journal of the National Cancer Institute Monographs 30 56-61.
11. Buzdar A, Kau S, Smith T & Hortobagyi G 1989 Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. American Journal of Clinical Oncology 12 123-128.
12. Buzdar A, Singletary S, Theriault R, Booser D, Valero V, Ibrahim N, Smith T, Asmar L, Frye D, Manuel N, Kau S, McNeese M, Strom E, Hunt K, Ames F & Hortobagyi G 1999 Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. Journal of Clinical Oncology 1734 3412-3417.
13. Buzdar A, Singletary S, Valero V, Booser D, Ibrahim N, Rahman Z, Theriault R, Walters R, Rivera E, Smith T, Holmes F, Hoy E, Frye D, Manuel N, Kau S, McNeese M, Strom E, Thomas E, Hunt K, Ames F, Berry D & Hortobagyi G 2002 Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clinical Cancer Research 8 1073-1079.
14. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber R, Rudenstam C, Collins J, Lindtner J, Hacking A, Cortes-Funes H & Forbes J 1994 The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Annals of Oncology 5 717-724.
15. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A & Crown J 1999 Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. Journal of Clinical Oncology 17 2341-2354.
16. Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L, Wolter J, Paton V, Shak S, Lieberman G & Slamon D 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology 9 2639-2648.
17. Curtis R, Boice J, Stovall M, Bernstein L, Greenberg R, Flannery J, Schwartz A, Weyer P, Moloney W & Hoover R 1992 Risk of leukemia after chemotherapy and radiation treatment for breast cancer. New England Journal of Medicine 326 1745-1751.
18. Davidson N, O'Neill A, Vukov A, Osborne C, Martino S, White D & Abeloff M 1999 Effect of chemohormonal therapy in premenopausal, node positive, receptor positive breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Proceedings of the American Society of Clinical Oncology Abstract 249.
19. Diamandidou E, Buzdar A, Smith T, Frye D, Witjaksono M & Hortobagyi G 1996 Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas MD Anderson Cancer Center experience. Journal of Clinical Oncology 14 2722-2730.
20. Early Breast Cancer Trialists' Collaborative Group 1988 Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28 896 women. New England Journal of Medicine 319 1681-1692.
21. Early Breast Cancer Trialists' Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune, therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339 71-85.
22. Early Breast Cancer Trialists' Collaborative Group 1996 Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348 1189-1196.
23. Early Breast Cancer Trialists' Collaborative Group 1998a Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 1451-1467.
24. Early Breast Cancer Trialists' Collaborative Group 1998b Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352 930-942.
25. Early Breast Cancer Trialists' Collaborative Group 2000 5th Annual Meeting of the Early Breast Cancer Trialists' Collaborative Group. Oxford UK, 21-22 September, 2000.
26. Ejlertsen B, Dombernowsky P, Mouridsen H, Kamby C, Kjaeer M, Rose C, Andersen K, Jensen M, Bengtsson N & Bergh J 1999 Comparable effect of ovarian ablation and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients. Proceedings of the American Society of Clinical Oncology Abstract 248.
27. Feldman L, Hortobagyi G, Buzdar A, Ames F & Blumenschein G 1986 Pathologic assessment of response to induction chemotherapy in breast cancer. Cancer Research 46 2578-2581.
28. Fisher B, Carbone P, Economou S, Glass A, Lerner H. Redmond C, Zelen M, Band P, Katrych D, Wolmark N & Fisher E 1975 L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. New England Journal of Medicine 292 117-122.
29. Fisher B, Glass A, Redmond C, Fisher ER, Barton B, Such F, Carbone, P, Economou S, Foster R, Frelick R, Lerner H, Levitt M, Margolese R, MacFarlane J, Plotkin D, Shibata H & Volk H 1977 L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU). Cancer 39 2883-2903.
30. Fisher B, Redmond C, Dimitrov N, Bowman D, Legault-Poisson S, Wickerham D, Wolmark N, Fisher E, Margolese R & Sutherland C 1989 A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. New England Journal of Medicine 320 473-478.
31. Fisher B, Redmond B, Legault-Poisson S, Dimitrov N, Brown A, Wickerham D, Wolmark N, Margolese R, Bowman D & Glass A 1990 Postoperative chemotherapy and tamoxifen compared to tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years or older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. Journal of Clinical Oncology 8 1005-1018.
32. Fisher B, Dignam J, DeCillis A, Wickerham D & Wolmark N 1996a Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-receptor-positive tumors. Journal of the National Cancer Institute 88 1529-1542.
33. Fisher B, Dignam J, Mamounas E, Costantino J, Wickerham D, Redmond C, Wolmark N, Dimitrov N, Bowman D, Glass A, Atkins J, Abramson N, Sutherland C, Aron B & Margolese R 1996b Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen-receptor-negative tumors: eight year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate and fluorouracil. Journal of Clinical Oncology 14 1982-1992.
34. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese R, Cruz A, Fisher E, Wickerham D, Wolmark N, DeCillis A, Hoehn J, Lees A & Dimitrov N 1997a Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of Clinical Oncology 15 2483-2493.
35. Fisher B, Anderson S, Wickerham L, DeCillis A, Dimitrov N, Mamounas E, Wolmark K, Pugh R, Atkins J, Meyers F, Abramson N, Wolter J, Bornstin R, Levy L, Romond E, Caggiano V, Grimaldi M, Jochimsen P & Deckers P 1997b Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. Journal of Clinical Oncology 15 1858-1869.
36. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher E, Wickerham D, Begovic M, DeCillis A, Robidoux A, Margolese R, Cruz A, Hoehn J, Lees A, Dimitrov N & Bear H 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology 16 2672-2685.
37. Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins J, Fehrenbacher L, Henry P, Romond E, Lanier K, Davila E, Kardinal C, Laufman L, Pierce H, Abramson N, Keller A, Hamm J, Wickerham D, Begovic M, Tan-Chiu E, Tian W & Wolmark N 1999 Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. Journal of Clinical Oncology 17 3374-3388.
38. Fisher B, Dignam J, Bryant J & Wolmark N 2001a Five versus more than five years of tamoxifen for node-negative breast cancer: updated findings. Journal of the National Cancer Institute 93 684-690.
39. Fisher B, Jeong J, Dignam J, Anderson S, Mamounas E, Wickerham D & Wolmark N 2001b Findings from recent National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies in Stage I breast cancer. Journal of the National Cancer Institute Monographs 30 62-66.
40. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham D, Fisher E, Dimitrov N, Atkins J, Abramson N, Merajver S, Romond E, Kardinal C, Shibata H, Margolese R & Farrar W 2001c Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. Journal of Clinical Oncology 19 931-942.
41. Fossati R, Cofalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A & Liberati A 1998 Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31 510 women. Journal of Clinical Oncology 16 3439-3460.
42. French Adjuvant Study Group 2001 Benefit of high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. Journal of Clinical Oncology 19 602-611.
43. Green M, Buzdar A, Smith T, Ibrahim N, Valero V, Rosales M, Cristofanilli M, Booser D, Pusztai L, Rivera E, Theriault R, Carter C, Singletary S, Kuerer H, Hunt K, Strom E & Hortobagyi G 2002 Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3-week paclitaxel therapy followed by FAC - final results of a prospective study. Proceedings of the American Society of Clinical Oncology Abstract 135.
44. Greenlee, R, Hill-Harma M, Murray T & Thun M 2001 Cancer Statistics 2001 CA: A Cancer Journal for Clinicians 51 15-36.
45. Henderson I, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, Ingle J, Cooper M, Canellos G, Borden E, Gleming G, Holland J, Graziano S, Carpenter J, Muss H & Norton L 1998 Improved disease-free survival and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proceedings of the American Society of Clinical Oncology 17 101a.
46. Holmes F, Walters R, Theriault R, Forman A, Newton L, Raber M, Buzdar A, Frye D & Hortobagyi G 1991 Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. Journal of the National Cancer Institute 83 1797-1805.
47. Hortobagyi G, Frye D, Buzdar A, Ewer M, Fraschini G, Hug V, Ames F, Montague E, Carrasco C, Mackay B & Benjamin R 1989 Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63 37-45.
48. Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abelof M, Lyss A, Henderson C, Allred C, Dakhil S, Pierce I, Goodwin W, Caton J, Rivkin S, Chapman R & Osborne C 1998 CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node negative patients: first results of Intergroup trial INT 0102. Proceedings of the American Society of Clinical Oncology plenary session.
49. International Breast Cancer Study Group 1996 Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. Journal of Clinical Oncology 14 1885-1893.
50. Kjellgren K, Nissen-Meyer R & Norin T 1989 Perioperative adjuvant chemotherapy in breast cancer. Acta Oncologica 28 899-901.
51. Kuerer H, Sahin A & Hunt K 1999 Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Annals of Surgery 230 72-78.
52. Levine M, Gent M, Hryniuk W, Bramwell V, Abi-Zahra J, DePauw, S, Arnold A, Findlay B, Levin L & Skillings J 1990 A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. Journal of Clinical Oncology 8 1217-1225.
53. Ludwig Breast Cancer Study Group 1990 Combination adjuvant chemotherapy for node-positive breast cancer: inadequacy of a single perioperative cycle. New England Journal of Medicine 319 677-685.
54. Mouridsen H, Andersen J, Andersson M, Dombemowsky P, Ejlertsen B, Rose C, Sorensen P, Sandberg E, Andersen K, Jensen M, Bengtson N, Bergh J & Nordenskjold B 1999 Adjuvant anthracycline in breast cancer: improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proceedings of the American Society of Clinical Oncology 18 Abstract 254.
55. Nabholtz J, Senn H, Bezwoda W, Melnychuk D, Deschenes L, Douma J, Vandenverg T, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier J, Richel D, Nagykalnai T, Siedlecki P, Wiling N, Genot J, Hupperets P, Pannuti F, Skarlos D, Tomiak E, Murawsky M, Alakl M, Riva A & Aapro M 1999 Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. Journal of Clinical Oncology 17 1413-1424.
56. Nabholtz J, Pienkowski T, Mackey J, Pawlicki M, Guastalla J, Vogel C, Weaver C, Walley B, Martin M, Chap L, Tomiak E, Juhos E, Guevin R, Howell A, Hainsworth J, Fornander T, Blitz S, Gazel S, Loret C & Riva A 2002 Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001 study. Proceedings of the American Society of Clinical Oncology Abstract 141.
57. National Institutes of Health Consensus Development Panel 2001 National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-2, 2000. Journal of the National Cancer Institute 93 979-989.
58. National Surgical Adjuvant Breast and Bowel Project 2001 The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: preliminary results from NSABP B27. Breast Cancer and Research Treatment 69 Abstract 5.
59. Nissen-Meyer R, Kjellgren K & Mansson B 1971 Preliminary report from the Scandinavian Adjuvant Chemotherapy Study Group. Cancer Chemotherapy Reports 55 561-566.
60. Osborne C, Boldt D, Clark G & Trent J 1983 Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Research 43 3583-3585.
61. Osborne C, Boldt D & Estrada P 1984 Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Research 44 1433-1439.
62. Osborne C, Hobbs K & Clark G 1985 Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Research 45 584-590.
63. Osborne C, Coronado E & Robinson J 1987 Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. European Journal of Cancer and Clinical Oncology 23 1189-1196.
64. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher E, Lippman M, Wickerham L & Wolmark N 1998 erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. Journal of the National Cancer Institute 90 1361-1370.
65. Peters W, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P, Marks L, Cirrincione C, Wood W, Henderson I, Hurd D & Norton L 1999 A prospective randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALBG 9082/SWOG 911/NCIC MA-13. Proceedings of the American Society of Clinical Oncology plenary session.
66. Piccart M, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, Closon-Dejardin M, Dufrane J, Kerger J, Leibens F, Beauvois S, Bartholomeus S, Dolci S, Lobelle J, Paesmans M & Nogaret J 2001 Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. Journal of Clinical Oncology 19 3103-3110.
67. Pritchard K, Paterson A, Paul N, Zee B, Fine S & Pater J 1996 Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. Journal of Clinical Oncology 14 2731-2737.
68. Pritchard K, Paterson A, Fine S, Zee B, Shephard L, Abu-Zahra H, Ragaz J, Knowling M, Levine M, Verma S, Perrault D, Walde P, Bramwell V, Poljicak M, Boyd N, Warr D, Norris B, Bowman D, Armitage G, Weizel H & Buckman R 1997 Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 15 2302-2311.
69. Ravdin P, Green S, Albain K, Boucher V, Ingles J, Pritchard K, Shepard L, Davidson N, Hayes D, Clark G, Martino S, Osborne C & Allred D 1998 Initial report of the SWOG biological correlative study of c-erb-B2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with tamoxifen alone. Proceedings of the American Society of Clinical Oncology 17 97a.
70. Reichman B, Seidman A, Crown J, Heelan R, Hakes T, Lebwol K, Gilewski T, Surbone A, Currie V, Hudis C, Yao T, Klecker R, Jamis-Dow C, Collins J, Quinlivan S, Berkery R, Toomasi F, Canetta R, Fisherman J, Arbuch S & Norton L 1993 Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. Journal of Clinical Oncology 11 1943-1951.
71. Rivkin S, Green S & Metch B 1993 One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. Journal of Clinical Oncology 11 1710-1716.
72. Rivkin S, Greens S, O'Sullivan J, Cruz A, Abeloff M, Jewell W, & Osborne C 1996 Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. Journal of Clinical Oncology 14 46-51.
73. Rodenhuis S, Bontenbal M, Beex L, van der Wall E, Richel D, Nooij M, Boest E, Hupperets P, Westermann A, Dalesio O & de Vries D 2000 Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. Proceedings of the American Society of Clinical Oncology Abstract 286.
74. Scottish Cancer Trials Breast Group 1993 Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish Trial. Lancet 341 1293-1298.
75. Shapiro C, Hardenbergh P, Gelman R, Blanks D, Hauptman P, Recht A, Hayes D, Harris J & Henderson I 1998 Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. Journal of Clinical Oncology 16 3493-3501.
76. Singal P & Iliskovic N 1998 Doxorubicin-induced cardiomyopathy. New England Journal of Medicine 339 900-905.
77. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengttsson N, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H & Bergh J 1999 Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. European Journal of Cancer 35 1194-1201.
78. Slamon D, Clark G, Wong S, Levin W, Ullrich A & McGuire W 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 177-182.
79. Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Flelming T, Eiermann W, Wolter J, Pegram M, Baselga J & Norton L 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 344 783-792.
80. Smith I, Hyes S, Hutcheon A, Miller I, Payne S, Gilbert F, Ah-See A, Eremin O, Walker L, Sarkar T, Eggleton S & Ogston K 2002 Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. Journal of Clinical Oncology 20 1456-1466.
81. Smith R, Bryant J, DeCillis A & Anderson S 2001 Acute myeloid leukemia and myelodysplastic syndrome following doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the NSABP experience. Breast Cancer and Research Treatment 69 Abstract 209.
82. Stewart H, Forrest A, Everington D, McDonald C, Dewar J & Hawkins R 1996 Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. British Journal of Cancer 74 297-299.
83. Stewart H, Prescott R & Forrest A 2001 Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. Journal of the National Cancer Institute 93 456-462.
84. Swain S, Wilson J, Eleftherios M, Bryant J, Wickerham L, Fisher B & Wolmark N 2002 Estrogen receptor (ER) status of primary breast cancer is predictive of ER status of contralateral breast cancer (CBC). Proceedings of the American Society of Clinical Oncology Abstract 150.
85. Tallman M, Gray R, Bennet J, Variakojis D, Robert N, Wood W, Rowe J & Wiernik P 1995 Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. Journal of Clinical Oncology 13 1557-1563.
86. Tancini G, Bajetta E, Marchini S, Valagussa P, Bonadonna G & Veronesi U 1979 Preliminary 3-year results of 12 versus 6 cycles of surgical adjuvant CMF in premenopausal breast cancer. Cancer Clinical Trials 2 285-292.
87. Tancini G, Bonnadonna G, Valagussa P, Marchini S & Veronesi U 1983 Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. Journal of Clinical Oncology 1 2-10.
88. Thomas E, Buzdar A, Theriault R, Singletary S, Booser D, Valero V, Ibrahim N, Smith T, Frye D, Manuel N, Kau S, McNeese M & Hortobagyi G 2000 Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of a prospective randomized clinical trial. Proceedings of the American Society of Clinical Oncology Abstract 285.
89. Thor A, Berry D, Budman D, Muss H, Kute T, Henderson I, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L & Liu E 1998 erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. Journal of the National Cancer Institute 90 1346-1360.
90. Valagussa P, Zambetti M, Biasi S, Moliterni Z, Zucali R & Bonnadonna G 1994 Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Annals of Oncology 5 209-216.
91. Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L, Slamon D, Murphy M, Novotny W, Burchmore M, Shak S, Stewart S & Press M 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 3 719-726.
92. Weiss R, Rifkin R, Stewart F, Theriault R, Williams L, Herman A & Beveridge R 2000 High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet 355 999-1003.
93. Wils J, Bliss J, Marty M, Coombes G, Fontaine C, Morvan F, Olmos T, Perez-Lopez F, Vassilopoulos P, Woods E & Coombes R 1999 Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group. Journal of Clinical Oncology 17 1988-1995.
94. Winer E, Hudis C, Burstein H, Chlebowski R, Ingle J, Edge S, Mamounas E, Gralow J, Goldstein L, Pritchard K, Braun S, Cobleigh M, Langer A, Perotti J, Powles T, Whelan T & Browman G 2002 American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report. Journal of Clinical Oncology 20 1-15.
95. Wolmark N, Wang J, Mamounas E, Bryant J & Fisher B 2001 Preoperative chemotherapy in patients with operable breast cancer: nine-year results from NSABP B-18. Journal of the National Cancer Institute Monographs 30 96-102.
96. Wood W, Budman D, Korzun A, Coope M, Younger J, Hart R, Moore A, Ellerton J, Norton L, Ferree C, Ballow A, Frei E & Henderson I 1994 Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. New England Journal of Medicine 330 1255-1259.
97. Zambetti M, Moliterni A, Materazzo C, Stefanelli M, Cipriani S, Valagussa P, Bonadonna G, & Gianni L 2001 Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. Journal of Clinical Oncology 19 37-43.